{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:36:07Z","timestamp":1790271367310,"version":"4.1.0"},"reference-count":250,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.biopha.2020.110493","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T03:05:49Z","timestamp":1593745549000},"page":"110493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":137,"special_numbering":"C","title":["Natural history of COVID-19 and current knowledge on treatment therapeutic options"],"prefix":"10.1016","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9110-6350","authenticated-orcid":false,"given":"Wagner Gouvea","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110493_bib0005","unstructured":"World Health Organization. https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-mission-briefing-on-covid-19---12-march-2020. (accessed May 16, 2020)."},{"issue":"8","key":"10.1016\/j.biopha.2020.110493_bib0010","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc2005696","article-title":"Death from Covid-19 of 23 health care workers in China","author":"Zhan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","author":"Verity","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.biopha.2020.110493_bib0025","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3390\/v12020135","article-title":"Return of the coronavirus: 2019-nCoV","volume":"12","author":"Gralinski","year":"2020","journal-title":"Viruses"},{"issue":"7798","key":"10.1016\/j.biopha.2020.110493_bib0030","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110493_bib0035","series-title":"Naming the Coronavirus Disease (COVID-19) and the Virus That Causes It","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.biopha.2020.110493_bib0040","unstructured":"Virological.org. Novel 2019 Coronavirus Genome. http:\/\/virological.org\/t\/issues-with-sars-cov-2-sequencing-data\/473 (accessed 16 May, 2020)."},{"issue":"13","key":"10.1016\/j.biopha.2020.110493_bib0045","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib0050","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008421","article-title":"Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)?","volume":"16","author":"Liu","year":"2020","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2020.110493_bib0060","series-title":"Pangolin Homology Associated With 2019-nCoV bioRxiv","author":"Zhang","year":"2020"},{"key":"10.1016\/j.biopha.2020.110493_bib0065","series-title":"Mission summary: WHO Field Visit to Wuhan, China","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.biopha.2020.110493_bib0070","series-title":"27,000 Viral Genomic Sequences of hCoV-19 Shared With Unprecedented Speed Via GISAID","author":"Global Initiative on Sharing All Influenza Data","year":"2020"},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib0075","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0080","doi-asserted-by":"crossref","first-page":"104212","DOI":"10.1016\/j.meegid.2020.104212","article-title":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event","volume":"79","author":"Paraskevis","year":"2020","journal-title":"Infect. Genet. Evol."},{"issue":"69","key":"10.1016\/j.biopha.2020.110493_bib0085","first-page":"1","article-title":"Coronavirus envelope protein: current knowledge","volume":"16","author":"Schoeman","year":"2019","journal-title":"Virol. J."},{"issue":"6485","key":"10.1016\/j.biopha.2020.110493_bib0090","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0095","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2020.110493_bib0100","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.biopha.2020.110493_bib0105","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00127-20","article-title":"Receptor recognition by the novel coronavirus from Wuhan: analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"180","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2020.110493_bib0115","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.biopha.2020.110493_bib0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41575-020-0295-7","article-title":"COVID-19: faecal\u2013oral transmission?","volume":"17","author":"Hindson","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"16","key":"10.1016\/j.biopha.2020.110493_bib0125","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMc2004973","article-title":"Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1","volume":"382","author":"Van Doremalen","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib0130","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/s41591-020-0817-4","article-title":"Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding","volume":"26","author":"Xu","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0135","first-page":"202009637","article-title":"Identifying airborne transmission as the dominant route for the spread of COVID-19","author":"Zhang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1\u20133","key":"10.1016\/j.biopha.2020.110493_bib0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12026-014-8534-z","article-title":"T cell-mediated immune response to respiratory coronaviruses","volume":"59","author":"Channappanavar","year":"2014","journal-title":"Immunol. Res."},{"issue":"10","key":"10.1016\/j.biopha.2020.110493_bib0145","doi-asserted-by":"crossref","first-page":"961","DOI":"10.3390\/v11100961","article-title":"Viral innate immune evasion and the pathogenesis of emerging rna virus infections","volume":"11","author":"Nelemans","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2020.110493_bib0150","article-title":"Can people with asymptomatic or pre-symptomatic COVID-19 infect others: a systematic review of primary data","author":"Aguirre-Duarte","year":"2020","journal-title":"medRxiv"},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0155","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1007\/s11427-020-1661-4","article-title":"Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China","volume":"63","author":"Hu","year":"2020","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.biopha.2020.110493_bib0160","series-title":"Protect Youself","author":"Center for Disease Control","year":"2020"},{"issue":"2","key":"10.1016\/j.biopha.2020.110493_bib0165","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2020.110493_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2017.11.012","article-title":"Wild-type human coronaviruses prefer cell-surface TMPRSS2 to endosomal cathepsins for cell entry","volume":"517","author":"Shirato","year":"2018","journal-title":"Virology"},{"issue":"8","key":"10.1016\/j.biopha.2020.110493_bib0175","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","article-title":"SARS and MERS: recent insights into emerging coronaviruses","volume":"14","author":"de Wit","year":"2016","journal-title":"Nat. Rev. Microbiol."},{"issue":"10223","key":"10.1016\/j.biopha.2020.110493_bib0180","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"issue":"10223","key":"10.1016\/j.biopha.2020.110493_bib0185","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.biopha.2020.110493_bib0190","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"China medical treatment expert group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10223","key":"10.1016\/j.biopha.2020.110493_bib0195","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.biopha.2020.110493_bib0200","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia","volume":"382","author":"Li","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib0205","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jinf.2020.02.018","article-title":"Characteristics of COVID-19 infection in Beijing","volume":"80","author":"Tian","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.biopha.2020.110493_bib0210","doi-asserted-by":"crossref","DOI":"10.1002\/alr.22610","article-title":"Smell and taste alterations in Covid-19: a cross-sectional analysis of different cohorts","author":"Paderno","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.biopha.2020.110493_bib0215","doi-asserted-by":"crossref","DOI":"10.1177\/0194599820926464","article-title":"Olfactory dysfunction: a highly prevalent symptom of COVID-19 with public health significance","author":"Sedaghat","year":"2020","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.biopha.2020.110493_bib0220","doi-asserted-by":"crossref","DOI":"10.1002\/alr.22579","article-title":"Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms","author":"Yan","year":"2020","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.biopha.2020.110493_bib0225","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib0230","article-title":"Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages","author":"Merad","year":"2020","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0235","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0240","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.110493_bib0245","article-title":"Dysregulation of immune response in patients with COVID-19 in Wuhan, China","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"10229","key":"10.1016\/j.biopha.2020.110493_bib0250","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110493_bib0255","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000115","article-title":"H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice","volume":"4","author":"Perrone","year":"2008","journal-title":"PLoS Pathog."},{"issue":"3","key":"10.1016\/j.biopha.2020.110493_bib0260","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1128\/CVI.00636-12","article-title":"Targeting the \u2018cytokine storm\u2019 for therapeutic benefit","volume":"20","author":"D\u2019Elia","year":"2013","journal-title":"Clin. Vaccine Immunol."},{"key":"10.1016\/j.biopha.2020.110493_bib0265","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1378\/chest.108.5.1303","article-title":"Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome","volume":"108","author":"Meduri","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.biopha.2020.110493_bib0270","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1471-2466-4-6","article-title":"The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome","volume":"4","author":"Bouros","year":"2004","journal-title":"BMC Pulm. Med."},{"issue":"9","key":"10.1016\/j.biopha.2020.110493_bib0275","doi-asserted-by":"crossref","first-page":"7639","DOI":"10.18632\/aging.103101","article-title":"Immune environment modulation in pneumonia patients caused by coronavirus: SARS-CoV, MERS-CoV and SARS-CoV-2","volume":"12","author":"Yao","year":"2020","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0280","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.biopha.2020.110493_bib0285","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"Wong","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.biopha.2020.110493_bib0290","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"Mahallawi","year":"2018","journal-title":"Cytokine"},{"key":"10.1016\/j.biopha.2020.110493_bib0295","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s11926-015-0529-9","article-title":"Contribution of the IL-17 pathway to psoriasis and psoriatic arthritis","volume":"17","author":"Durham","year":"2015","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.biopha.2020.110493_bib0300","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic rationales for targeting interleukin17A in spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.biopha.2020.110493_bib0305","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41577-020-0328-z","article-title":"COVID-19: a case for inhibiting IL-17?","volume":"20","author":"Pacha","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.110493_bib0310","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","author":"Gao","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0315","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bcp.2009.09.015","article-title":"From IL-15 to IL-33: the never-ending list of new players in inflammation. Is it time to forget the humble aspirin and move ahead?","volume":"79","author":"D\u2019Acquisto","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.biopha.2020.110493_bib0320","doi-asserted-by":"crossref","first-page":"104791","DOI":"10.1016\/j.phrs.2020.104791","article-title":"Could IL-17 represent a new therapeutic target for the treatment and\/or management of COVID-19-related respiratory syndrome?","volume":"156","author":"Casillo","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"7","key":"10.1016\/j.biopha.2020.110493_bib0325","doi-asserted-by":"crossref","first-page":"102572","DOI":"10.1016\/j.autrev.2020.102572","article-title":"Interleukin-17A (IL-17A), a key molecule of innate and adaptive immunity, and its potential involvement in COVID-19-related thrombotic and vascular mechanisms","volume":"19","author":"Raucci","year":"2020","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.biopha.2020.110493_bib0330","doi-asserted-by":"crossref","first-page":"104933","DOI":"10.1016\/j.phrs.2020.104933","article-title":"Letter to the Editor in response to the article \u201cCould IL-17 represent a new therapeutic target for the treatment and\/or management of COVID-19-related respiratory syndrome?\u201d","volume":"158","author":"Ceccarelli","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmii.2020.03.005","article-title":"TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor fedratinib","author":"Wu","year":"2020","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"10.1016\/j.biopha.2020.110493_bib0340","article-title":"COVID-19 cytokine storm: the interplay between inflammation and coagulation","volume":"20","author":"Jose","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0345","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2018.10.007","article-title":"Lambda interferons come to light: dual function cytokines mediating antiviral immunity and damage control","volume":"56","author":"Andreakos","year":"2019","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.biopha.2020.110493_bib0350","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2017.00119","article-title":"Interferon lambda: modulating immunity in infectious diseases","volume":"8","author":"Syedbasha","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2020.110493_bib0355","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2017.04.025","article-title":"Interferon-lambda mediates nonredundant front-line antiviral protection against influenza virus infection without compromising host fitness","volume":"46","author":"Galani","year":"2017","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.biopha.2020.110493_bib0360","doi-asserted-by":"crossref","first-page":"e12465","DOI":"10.15252\/emmm.202012465","article-title":"COVID-19: lambda interferon against viral load and hyperinflammation","volume":"12","author":"Andreakos","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0365","first-page":"1","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2020.110493_bib0370","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41564-020-0713-1","article-title":"SARS-CoV-2 detection in patients with influenza-like illness","volume":"5","author":"Kong","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.biopha.2020.110493_bib0375","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.2020200241","article-title":"Chest CT findings in 2019 novel coronavirus (2019-nCoV) infections from Wuhan, China: key points for the radiologist","author":"Kanne","year":"2020","journal-title":"Radiology"},{"key":"10.1016\/j.biopha.2020.110493_bib0380","first-page":"1","article-title":"CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China","volume":"5","author":"Zhou","year":"2020","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.biopha.2020.110493_bib0385","doi-asserted-by":"crossref","DOI":"10.1007\/s00134-020-06033-2","article-title":"COVID-19 pneumonia: different respiratory treatments for different phenotypes?","author":"Gattinoni","year":"2020","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0390","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s10930-020-09901-4","article-title":"The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19","volume":"39","author":"Yoshimoto","year":"2020","journal-title":"Protein J."},{"key":"10.1016\/j.biopha.2020.110493_bib0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002433","article-title":"SARS coronavirus nsp1 protein induces template-dependent endonucleolytic cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA cleavage","volume":"7","author":"Huang","year":"2011","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2020.110493_bib0400","doi-asserted-by":"crossref","first-page":"10314","DOI":"10.1128\/JVI.00842-09","article-title":"Severe acute respiratory syndrome coronavirus nonstructural protein 2 interacts with a host protein complex involved in mitochondrial biogenesis and intracellular signaling","volume":"83","author":"Cornillez-Ty","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0405","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.antiviral.2017.11.001","article-title":"Nsp3 of coronaviruses: structures and functions of a large multi-domain protein","volume":"149","author":"Lei","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0410","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","article-title":"The SARS coronavirus papain-like protease: structure, function, and inhibition by designed antiviral compounds","volume":"115","author":"Baez-Santos","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0415","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.virol.2017.07.019","article-title":"Two-amino acids change in the nsp4 of SARS coronavirus abolishes viral replication","volume":"510","author":"Sakai","year":"2017","journal-title":"Virology"},{"key":"10.1016\/j.biopha.2020.110493_bib0420","doi-asserted-by":"crossref","first-page":"19403","DOI":"10.1074\/jbc.M115.651463","article-title":"Ligand induced dimerization of middle east respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro) implications for nsp5 Regulation and the Development of Antivirals","volume":"290","author":"Tomar","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.110493_bib0425","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.4161\/auto.29309","article-title":"Coronavirus NSP6 restricts autophagosome expansion","volume":"10","author":"Cottam","year":"2014","journal-title":"Autophagy"},{"key":"10.1016\/j.biopha.2020.110493_bib0430","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/nar\/gkr893","article-title":"The SARScoronavirus nsp7+nsp8 complex is a unique multimeric RNA polymerase capable of both de novo initiation and primer extension","volume":"40","author":"Te Velthuis","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0435","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.virusres.2014.10.021","article-title":"The DEAD-box RNA helicase 5 positively regulates the replication of porcine reproductive and respiratory syndrome virus by interacting with viral Nsp9 in vitro","volume":"195","author":"Zhao","year":"2015","journal-title":"Virus Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0440","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1073\/pnas.1508686112","article-title":"Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex","volume":"112","author":"Ma","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2020.110493_bib0445","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/JVI.00948-15","article-title":"Coronavirus nsp10\/nsp16 methyltransferase can be targeted by nsp10-derived peptide in vitro and in vivo to reduce replication and pathogenesis","volume":"89","author":"Wang","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0450","doi-asserted-by":"crossref","first-page":"E3900","DOI":"10.1073\/pnas.1323705111","article-title":"One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities","volume":"111","author":"Subissi","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2020.110493_bib0455","doi-asserted-by":"crossref","first-page":"5619","DOI":"10.1128\/JVI.78.11.5619-5632.2004","article-title":"Multiple enzymatic activities associated with severe acute respiratory syndrome coronavirus helicase","volume":"78","author":"Ivanov","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0460","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1128\/JVI.00542-16","article-title":"Mutagenesis of S-adenosyl-l-methionine-binding residues in coronavirus nsp14 N7-methyltransferase demonstrates differing requirements for genome translation and resistance to innate immunity","volume":"90","author":"Case","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0465","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jmb.2006.06.021","article-title":"RNA recognition and cleavage by the SARS coronavirus endoribonuclease","volume":"361","author":"Bhardwaj","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.biopha.2020.110493_bib0470","doi-asserted-by":"crossref","first-page":"8094","DOI":"10.1073\/pnas.1921485117","article-title":"C Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors","volume":"117","author":"Hackbart","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2020.110493_bib0475","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002059","article-title":"Crystal structure and functional analysis of the sars-coronavirus RNA cap 2\u2019-O-methyltransferase nsp10\/nsp16 complex","volume":"7","author":"Decroly","year":"2011","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0480","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2020.110493_bib0485","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3390\/v12040445","article-title":"Molecular investigation of SARS-CoV-2 proteins and their interactions with antiviral drugs","volume":"12","author":"Calligari","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2020.110493_bib0490","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110493_bib0495","doi-asserted-by":"crossref","first-page":"129","DOI":"10.12688\/f1000research.22457.2","article-title":"Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates","volume":"9","author":"Chen","year":"2020","journal-title":"F1000Res"},{"issue":"50","key":"10.1016\/j.biopha.2020.110493_bib0500","doi-asserted-by":"crossref","first-page":"14408","DOI":"10.1073\/pnas.1618029113","article-title":"Zika virus cell tropism in the developing human brain and inhibition by azithromycin","volume":"113","author":"Retallack","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.biopha.2020.110493_bib0505","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1021\/acsinfecdis.5b00030","article-title":"Evaluation of Ebola virus inhibitors for drug repurposing","volume":"1","author":"Madrid","year":"2015","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib0510","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ppul.1076","article-title":"Anti\u2010inflammatory effects of macrolides in lung disease","volume":"31","author":"Jaff\u00e9","year":"2001","journal-title":"Pediatr. Pulmonol."},{"issue":"10095","key":"10.1016\/j.biopha.2020.110493_bib0515","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)31281-3","article-title":"Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Gibson","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110493_bib0520","doi-asserted-by":"crossref","first-page":"28698","DOI":"10.1038\/srep28698","article-title":"Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients","volume":"6","author":"Menzel","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2020.110493_bib0525","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1089\/jir.2010.0063","article-title":"Mechanisms of type III interferon expression","volume":"30","author":"Iversen","year":"2010","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0530","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.coviro.2011.11.001","article-title":"Induction and function of type I and III interferon in response to viral infection","volume":"6","author":"Levy","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0535","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS\u2010CoV\u20102 replication","author":"Touret","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2020.110493_bib0540","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.1857","article-title":"Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID\u201019","author":"Damle","year":"2020","journal-title":"Clin. Pharm. Therap."},{"key":"10.1016\/j.biopha.2020.110493_bib0545","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110493_bib0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection","author":"Molina","year":"2020","journal-title":"Med. Mal. Infect."},{"issue":"7","key":"10.1016\/j.biopha.2020.110493_bib0555","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1093\/rheumatology\/36.7.799","article-title":"Antimalarial drugs in the treatment of rheumatological diseases","volume":"36","author":"Rynes","year":"1997","journal-title":"Rheumatology"},{"key":"10.1016\/j.biopha.2020.110493_bib0560","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12016-010-8243-x","article-title":"Hydroxychloroquine: from malaria to autoimmunity","volume":"42","author":"Ben-Zvi","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.biopha.2020.110493_bib0565","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"Gao","year":"2020","journal-title":"Biosci. Trends"},{"key":"10.1016\/j.biopha.2020.110493_bib0570","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbrc.2004.08.085","article-title":"In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine","volume":"323","author":"Keyaerts","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2020.110493_bib0575","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2020.110493_bib0580","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib0585","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.biopha.2020.110493_bib0590","doi-asserted-by":"crossref","first-page":"105980","DOI":"10.1016\/j.ijantimicag.2020.105980","article-title":"Chloroquine as a prophylactic agent against COVID-19?","author":"Gendrot","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110493_bib0595","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jcrc.2020.03.005","article-title":"A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19","volume":"57","author":"Cortegiani","year":"2020","journal-title":"J. Crit. Care"},{"key":"10.1016\/j.biopha.2020.110493_bib0600","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0605","doi-asserted-by":"crossref","DOI":"10.1007\/s10928-020-09689-x","article-title":"Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome","author":"Okour","year":"2020","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"10.1016\/j.biopha.2020.110493_bib0610","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today\u2019s diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib0615","series-title":"EUA Hydroxychloroquine Sulfate Health Care Provider: Fact Sheet for Patients and parent\/caregivers Emergency Use Authorization (EUA) of Hydroxychloroquine Sulfate for Treatment of COVID-19 in Certain Hospitalized Patients","author":"U.S. Food and Drug Administration","year":"2020"},{"issue":"0","key":"10.1016\/j.biopha.2020.110493_bib0620","first-page":"E019","article-title":"Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novelcoronavirus pneumonia","volume":"43","year":"2020","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"10.1016\/j.biopha.2020.110493_bib0625","author":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios"},{"key":"10.1016\/j.biopha.2020.110493_bib0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"3","key":"10.1016\/j.biopha.2020.110493_bib0635","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.161063","article-title":"Increased incidence of gastrointestinal side effects in patients taking hydroxychloroquine: a brand-related issue?","volume":"44","author":"Srinivasa","year":"2017","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2020.110493_bib0640","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1136\/ard.55.3.187","article-title":"Retinal toxicity in long term hydroxychloroquine treatment","volume":"55","author":"Mavrikakis","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib0645","series-title":"Seminars in Arthritis and Rheumatism","first-page":"62","article-title":"The ocular safety of hydroxychloroquine","author":"Easterbrook","year":"1993"},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0650","first-page":"649","article-title":"Hydroxychloroquine and chloroquine retinopathy: screening for drug toxicity","volume":"133","author":"Browning","year":"2002","journal-title":"Am. J. Ophthalmol. Case Rep."},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0655","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/hrt.69.5.451","article-title":"Restrictive cardiomyopathy caused by chloroquine","volume":"69","author":"Cubero","year":"1993","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0660","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/rheumatology\/kel402","article-title":"Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases","volume":"46","author":"Costedoat-Chalumeau","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.biopha.2020.110493_bib0665","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.120.008662","article-title":"The Effect of Chloroquine, Hydroxychloroquine and Azithromycin on the Corrected QT Interval in Patients with SARS-CoV-2 Infection","author":"Saleh","year":"2020","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"10.1016\/j.biopha.2020.110493_bib0670","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mehra","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.biopha.2020.110493_bib0675","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2020.110493_bib0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104760","article-title":"The broad spectrum antiviral ivermectin targets the host nuclear transport importin \u03b1\/\u03b21 heterodimer","volume":"177","author":"Yang","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro","volume":"178","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0690","article-title":"The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19","author":"Schmith","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2020.110493_bib0695","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.vetpar.2004.11.028","article-title":"Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat","volume":"128","author":"Lespine","year":"2005","journal-title":"Vet. Parasitol."},{"key":"10.1016\/j.biopha.2020.110493_bib0700","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"HKU\/UCH SARS Study Group. Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"Chu","year":"2004","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib0705","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs:25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110493_bib0710","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.biopha.2020.110493_bib0715","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small molecules targeting severe acute respiratory syndrome human coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2020.110493_bib0720","first-page":"399","article-title":"Treatment of severe acute respiratory syndrome with lopinavir\/ritonavir: A multicentre retrospective matched cohort study","volume":"9","author":"Chan","year":"2003","journal-title":"Hong Kong Med. J."},{"issue":"6","key":"10.1016\/j.biopha.2020.110493_bib0725","doi-asserted-by":"crossref","first-page":"e79","DOI":"10.3346\/jkms.2020.35.e79","article-title":"Case of the index patient who caused tertiary transmission of COVID19 infection in Korea: the application of lopinavir\/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR","volume":"35","author":"Lim","year":"2020","journal-title":"J. Korean Med. Sci."},{"issue":"19","key":"10.1016\/j.biopha.2020.110493_bib0730","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19","volume":"382","author":"Cao","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.biopha.2020.110493_bib0735","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jiph.2016.04.001","article-title":"Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus","volume":"9","author":"Rossignol","year":"2016","journal-title":"J. Infection Public Health"},{"issue":"7","key":"10.1016\/j.biopha.2020.110493_bib0740","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1473-3099(14)70717-0","article-title":"Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b\/3 trial","volume":"14","author":"Haffizulla","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib0745","doi-asserted-by":"crossref","first-page":"104874","DOI":"10.1016\/j.phrs.2020.104874","article-title":"Nitazoxanide\/azithromycin combination for COVID-19: A suggested new protocol for early management [published online ahead of print, 2020 Apr 30]","volume":"157","author":"Kelleni","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.biopha.2020.110493_bib0750","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S2055-6640(20)30017-0","article-title":"Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19","volume":"6","author":"Pepperrell","year":"2020","journal-title":"J. Virus Erad."},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0755","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/acs.jmedchem.6b01594","article-title":"Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses","volume":"60","author":"Siegel","year":"2017","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0760","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2020.110493_bib0765","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMoa2001191","article-title":"First case of 2019 novel coronavirus in the United States","volume":"382","author":"Holshue","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0770","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","author":"Grein","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"10236","key":"10.1016\/j.biopha.2020.110493_bib0775","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.biopha.2020.110493_bib0780","article-title":"The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5\u2019-triphosphate towards influenza A virus polymerase","volume":"8","author":"Jin","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.biopha.2020.110493_bib0785","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.biopha.2020.110493_bib0790","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.antiviral.2018.03.003","article-title":"Favipiravir as a potential countermeasure against neglected and emerging RNA viruses","volume":"153","author":"Delang","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0795","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104786","article-title":"Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro","volume":"178","author":"Choy","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.biopha.2020.110493_bib0800","article-title":"Favipiravir versus arbidol for COVID-19: a randomized clinical trial","author":"Chen","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.biopha.2020.110493_bib0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental treatment with favipiravir for COVID-19: an open-label control study","author":"Cai","year":"2020","journal-title":"Engineering"},{"issue":"10","key":"10.1016\/j.biopha.2020.110493_bib0810","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: a broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr. Med. Chem."},{"issue":"25","key":"10.1016\/j.biopha.2020.110493_bib0815","doi-asserted-by":"crossref","first-page":"8544","DOI":"10.1021\/jp102619w","article-title":"Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes","volume":"114","author":"Villala\u00edn","year":"2010","journal-title":"J. Phys. Chem. B"},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0820","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.biopha.2020.110493_bib0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2020.03.002","article-title":"Arbidol combined with LPV\/r versus LPV\/r alone against corona virus disease 2019: a retrospective cohort study","author":"Dong","year":"2020","journal-title":"J. Infect."},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0830","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jinf.2020.03.060","article-title":"Arbidol monotherapy is superior to lopinavir\/ritonavir in treating COVID-19","volume":"81","author":"Zhu","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.biopha.2020.110493_bib0835","doi-asserted-by":"crossref","DOI":"10.1001\/jamainternmed.2020.0994","article-title":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","author":"Wu","year":"2020","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0840","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41392-020-0158-2","article-title":"A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0845","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41392-020-0127-9","article-title":"Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia","volume":"5","author":"Zhou","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.biopha.2020.110493_bib0850","series-title":"Dexamethasone Reduces Death in Hospitalised Patients With Severe Respiratory Complications of COVID-19","author":"Oxford","year":"2020"},{"issue":"10223","key":"10.1016\/j.biopha.2020.110493_bib0855","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0140-6736(20)30211-7","article-title":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","volume":"395","author":"Chen","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110493_bib0860","doi-asserted-by":"crossref","DOI":"10.1111\/jth.14768","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2020.110493_bib0865","article-title":"Comprehensive treatment and management of coronavirus disease 2019: expert consensus statement from Shanghai (in Chinese)","volume":"38","author":"Shanghai Clinical Treatment Expert Group for COVID-19","year":"2020","journal-title":"Chin. J. Infect. Dis"},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0870","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.biopha.2020.110493_bib0875","article-title":"Heparin therapy improving hypoxia in COVID-19 patients - a case series. S\u00e3o Paulo","author":"Negri","year":"2020","journal-title":"MedRxiv"},{"key":"10.1016\/j.biopha.2020.110493_bib0880","first-page":"1","article-title":"Cardiac and arrhythmic complications in patients with COVID-19","author":"Kochi","year":"2020","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"10.1016\/j.biopha.2020.110493_bib0885","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fcvm.2018.00067","article-title":"Heparin oligosaccharides have antiarrhythmic effect by accelerating the sodium-calcium exchanger","volume":"5","author":"Godoy","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0890","article-title":"Straight to the heart: pleiotropic antiarrhythmic actions of oral anticoagulants","volume":"145","author":"Fender","year":"2019","journal-title":"Pharmacol. Res. Elsevier"},{"key":"10.1016\/j.biopha.2020.110493_bib0895","article-title":"Anticoagulant and antiarrhythmic effects of heparin in the treatment of COVID-19 patients [published online ahead of print, 2020 May 14]","author":"Menezes-Rodrigues","year":"2020","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0900","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1family ininnate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2020.110493_bib0905","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1164\/ajrccm.164.10.2104013","article-title":"Cytokine balance in the lungs of patients with acute respiratory distress syndrome","volume":"164","author":"Park","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.biopha.2020.110493_bib0910","first-page":"2134","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.biopha.2020.110493_bib0915","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study","author":"Cavalli","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110493_bib0920","doi-asserted-by":"crossref","DOI":"10.1016\/S2665-9913(20)30164-8","article-title":"Anakinra for severe forms of COVID-19: a cohort study","author":"Huet","year":"2020","journal-title":"Lancet Rheumath."},{"key":"10.1016\/j.biopha.2020.110493_bib0925","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.biopha.2020.110493_bib0930","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110493_bib0935","article-title":"Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact [published online ahead of print, 2020 Apr 23]","author":"Cantini","year":"2020","journal-title":"J. Infect."},{"key":"10.1016\/j.biopha.2020.110493_bib0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102452","article-title":"Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?","author":"Liu","year":"2020","journal-title":"J. Autoimmunity"},{"key":"10.1016\/j.biopha.2020.110493_bib0945","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.berh.2012.01.001","article-title":"Tocilizumab\u2014a novel therapy for non-organ-specific autoimmune diseases","volume":"26","author":"Kaly","year":"2012","journal-title":"Best Pract. Res. Clin. Rheumatol."},{"issue":"20","key":"10.1016\/j.biopha.2020.110493_bib0950","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","article-title":"Effective treatment of severe COVID-19 patients with tocilizumab","volume":"117","author":"Xu","year":"2020","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib0955","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1146\/annurev-virology-100114-055249","article-title":"No love lost between viruses and interferons","volume":"2","author":"Fenster","year":"2015","journal-title":"Annu. Rev. Virol."},{"issue":"5","key":"10.1016\/j.biopha.2020.110493_bib0960","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.cytogfr.2014.06.002","article-title":"Tyrosine phosphorylation in Toll-like receptor signaling","volume":"25","author":"Chattopadhyay","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"issue":"2","key":"10.1016\/j.biopha.2020.110493_bib0965","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.it.2013.10.010","article-title":"STING-dependent cytosolic DNA sensing pathways","volume":"35","author":"Barber","year":"2014","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.biopha.2020.110493_bib0970","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.molcel.2014.03.040","article-title":"The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling","volume":"54","author":"Cai","year":"2014","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2020.110493_bib0975","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1146\/annurev-immunol-032713-120231","article-title":"Interferon-stimulated genes: a complex web of host defenses","volume":"32","author":"Schneider","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.110493_bib0980","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/infdis\/jiv392","article-title":"Treatment with lopinavir\/ritonavir or interferon-\u03b21b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset","volume":"212","author":"Chan","year":"2015","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib0985","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104811","article-title":"Potent antiviral activities of type I interferons to SARS-CoV-2 infection","volume":"179","author":"Mantlo","year":"2020","journal-title":"Antiviral Res."},{"issue":"10238","key":"10.1016\/j.biopha.2020.110493_bib0990","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"issue":"6965","key":"10.1016\/j.biopha.2020.110493_bib0995","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib1000","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.bbrc.2020.02.071","article-title":"Structure analysis of the receptor binding of 2019-nCoV","volume":"525","author":"Chen","year":"2020","journal-title":"Biochem. Biophys. Res. Com."},{"issue":"2","key":"10.1016\/j.biopha.2020.110493_bib1005","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and Antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib1010","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.biopha.2020.110493_bib1015","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib1020","first-page":"14238","article-title":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China","author":"Zhang","year":"2020","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib1025","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib1030","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-05073-9","article-title":"Rheumatologists\u2019 perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets","author":"Misra","year":"2020","journal-title":"Clin. Rheumatol."},{"issue":"25","key":"10.1016\/j.biopha.2020.110493_bib1035","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMe2012924","article-title":"Inhibitors of the renin-angiotensin-Aldosterone system and Covid-19","volume":"382","author":"Jarcho","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib1040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026777","article-title":"Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis","volume":"9","author":"Smyth","year":"2019","journal-title":"BMJ Open"},{"issue":"14","key":"10.1016\/j.biopha.2020.110493_bib1045","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1073\/pnas.1432869100","article-title":"Angiotensin\u2010(1\u20107) is an endogenous ligand for the G protein\u2010coupled receptor Mas","volume":"100","author":"Santos","year":"2003","journal-title":"PNAS"},{"key":"10.1016\/j.biopha.2020.110493_bib1050","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.21656","article-title":"Angiotensin receptor blockers as tentative SARSCoV-2 therapeutics","author":"Gurwitz","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.biopha.2020.110493_bib1055","doi-asserted-by":"crossref","first-page":"867","DOI":"10.2147\/COPD.S158634","article-title":"Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD","volume":"13","author":"Lai","year":"2018","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"issue":"11","key":"10.1016\/j.biopha.2020.110493_bib1060","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1093\/cid\/cis733","article-title":"Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes","volume":"55","author":"Mortensen","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib1065","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.1924","article-title":"ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust","author":"Bean","year":"2020","journal-title":"Eur. J. Heart Fail."},{"issue":"22","key":"10.1016\/j.biopha.2020.110493_bib1070","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/eurheartj\/ehaa433","article-title":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study","volume":"41","author":"Gao","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2020.110493_bib1075","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa634","article-title":"Therapy with agents acting on the renin-angiotensin system and risk of SARS-CoV-2 infection","author":"Gnavi","year":"2020","journal-title":"Clin. Infect. Dis."},{"issue":"10238","key":"10.1016\/j.biopha.2020.110493_bib1080","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(20)31030-8","article-title":"MED-ACE2-COVID19 study group. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","volume":"395","author":"de Abajo","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110493_bib1085","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00912-2020","article-title":"Understanding the Renin-Angiotensin-Aldosterone-SARS-CoV-Axis: a comprehensive review","author":"Ingraham","year":"2020","journal-title":"Eur. Respir. J."},{"issue":"17","key":"10.1016\/j.biopha.2020.110493_bib1090","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-Aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.biopha.2020.110493_bib1095","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1128\/AAC.38.8.1695","article-title":"Serum therapy revisited: animal models of infection and development of passive antibody therapy","volume":"38","author":"Casadevall","year":"1994","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.biopha.2020.110493_bib1100","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"Luke","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib1105","doi-asserted-by":"crossref","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","author":"Bloch","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib1110","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1172\/JCI138003","article-title":"The convalescent sera option for containing COVID-19","volume":"130","author":"Casadevall","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.biopha.2020.110493_bib1115","first-page":"ciaa344","article-title":"Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019","author":"Zhao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib1120","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2020.110493_bib1125","first-page":"202004168","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"Duan","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.biopha.2020.110493_bib1130","doi-asserted-by":"crossref","DOI":"10.3390\/nu9111211","article-title":"Vitamin C and immune function","volume":"9","author":"Carr","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2020.110493_bib1135","doi-asserted-by":"crossref","first-page":"708","DOI":"10.3390\/nu11040708","article-title":"Vitamin C can shorten the length of stay in the ICU: a metaanalysis","volume":"11","author":"Hemil\u00e4","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2020.110493_bib1140","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.chest.2016.11.036","article-title":"Hydrocortisone, vitamin C, and thiamine for the treatment of severe sepsis and septic shock: a retrospective before-after study","volume":"151","author":"Marik","year":"2017","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.biopha.2020.110493_bib1145","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/14787210.2020.1706483","article-title":"The antiviral properties of vitamin C","volume":"18","author":"Colunga-Biancatelli","year":"2020","journal-title":"Expert Rev. Anti. Ther."},{"key":"10.1016\/j.biopha.2020.110493_bib1150","doi-asserted-by":"crossref","first-page":"100190","DOI":"10.1016\/j.phanu.2020.100190","article-title":"Intravenous Vitamin C for reduction of cytokines storm in Acute Respiratory Distress Syndrome [published online ahead of print, 2020 Apr 21]","volume":"12","author":"Boretti","year":"2020","journal-title":"PharmaNutrition"},{"key":"10.1016\/j.biopha.2020.110493_bib1155","doi-asserted-by":"crossref","first-page":"100028","DOI":"10.1016\/j.medidd.2020.100028","article-title":"Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?","volume":"5","author":"Cheng","year":"2020","journal-title":"Med Drug Discov."},{"issue":"1","key":"10.1016\/j.biopha.2020.110493_bib1160","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13054-020-02851-4","article-title":"A new clinical trial to test high-dose vitamin C in patients with COVID-19","volume":"24","author":"Carr","year":"2020","journal-title":"Crit. Care"},{"key":"10.1016\/j.biopha.2020.110493_bib1165","doi-asserted-by":"crossref","DOI":"10.1111\/joim.12777","article-title":"Vitamin D and tuberculosis: where next?","author":"Brighenti","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.biopha.2020.110493_bib1170","doi-asserted-by":"crossref","first-page":"i6583","DOI":"10.1136\/bmj.i6583","article-title":"Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data","volume":"356","author":"Martineau","year":"2017","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.biopha.2020.110493_bib1175","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.dsx.2020.04.050","article-title":"Vitamin d concentrations and COVID-19 infection in UK Biobank","volume":"14","author":"Hastie","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"issue":"11","key":"10.1016\/j.biopha.2020.110493_bib1180","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001176","article-title":"Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture","volume":"6","author":"Te Velthuis","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.biopha.2020.110493_bib1185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3109\/01902140903061787","article-title":"Alteration in the expression of inflammatory parameters as a result of oxidative stress produced by moderate zinc deficiency in rat lung","volume":"36","author":"Biaggio","year":"2010","journal-title":"Exp. Lung Res."},{"key":"10.1016\/j.biopha.2020.110493_bib1190","doi-asserted-by":"crossref","first-page":"L1132","DOI":"10.1152\/ajplung.00207.2006","article-title":"Zinc modulates cytokine-induced lung epithelial cell barrier permeability","volume":"291","author":"Bao","year":"2006","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.biopha.2020.110493_bib1195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0109180","article-title":"Chloroquine is a zinc ionophore","volume":"9","author":"Xue","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110493_bib1200","article-title":"Treatment of SARS-CoV-2 with high dose oral zinc salts: a report on four patients [published online ahead of print, 2020 Jun 6]","author":"Finzi","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.biopha.2020.110493_bib1205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106020","article-title":"Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal","author":"Fantini","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.biopha.2020.110493_bib1210","article-title":"ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques","author":"Doremalen","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.biopha.2020.110493_bib1215","series-title":"Oxford COVID-19 Vaccine Begins Human Trial Stage","author":"Oxford","year":"2020"},{"key":"10.1016\/j.biopha.2020.110493_bib1220","series-title":"Moderna Announces Positive Interim Phase 1 Data for Its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus","author":"Moderna","year":"2020"},{"key":"10.1016\/j.biopha.2020.110493_bib1225","article-title":"Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2020.110493_bib1230","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/d41586-020-01695-w","article-title":"High-profile coronavirus retractions raise concerns about data oversight","volume":"582","author":"Ledford","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2020.110493_bib1235","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.4742","article-title":"Treating COVID-19\u2014off-label drug use, compassionate use, and randomized clinical trials during pandemics","author":"Kalil","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.biopha.2020.110493_bib1240","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.biopha.2020.110493_bib1245","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.biopha.2020.110493_bib1250","doi-asserted-by":"crossref","first-page":"105998","DOI":"10.1016\/j.ijantimicag.2020.105998","article-title":"Arbidol: a potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein","author":"Vankadari","year":"2020","journal-title":"Int. J. Antimicrob. Agents"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220306867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220306867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:19:15Z","timestamp":1760098755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220306867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":250,"alternative-id":["S0753332220306867"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110493","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural history of COVID-19 and current knowledge on treatment therapeutic options","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110493","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110493"}}